Diagnosis, Risk-Stratification, Management Updates in Myelodysplastic Syndromes
An overview of the diagnosis and management of MDS, including recent treatment, was discussed in a paper published in the American Journal of Hematology.
Multiple Myeloma
How the Coronavirus Pandemic May Affect Cancer Clinical Trials
Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.
BCMA-Directed CAR T Cell Therapy Gets Priority Review for Multiple Myeloma
The BLA is supported by data from the open-label, single-arm phase 2 KarMMa study.
Rapid Third-Infusion Protocol of Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma
An observational study determined that 90-minute rapid infusions of daratumumab for RRMM was safe and well-tolerated.
Multiple Myeloma: More Real-World Data Needed To Confirm Effectiveness of New Treatments
More data is needed to determine whether newer treatments are truly improving outcomes among patients with r/r multiple myeloma.
Outcomes After Daratumumab Addition to Induction Therapy in Newly Diagnosed Multiple Myeloma
Researchers assessed the effects of adding daratumumab to standard frontline induction therapy to treat MM in newly diagnosed, transplant-eligible patients.
Phase 1 Trial Featuring First shRNA-Edited CAR-T Therapy to Begin
FDA approves allogenic CAR T cells targeted at BCMA for phase 1 trial in relapsed/refractory multiple myeloma.
European Myeloma Network Provides Vaccine Recommendations for MM
Patients with myeloma should receive 2 doses of the trivalent or quadrivalent vaccine influenza vaccine and vaccinations should continue annually.
Gain in Chromosome 1q Should Be Considered High Risk in Myeloma
The cytogenetic abnormality was linked to inferior overall survival.
New Drug Product: Blenrep
This slideshow shows drug information for Blenrep. Click here for the complete Blenrep monograph.
-
Loading...
-
Loading...
